Trisalus Life Sciences, Inc.
Records under this name other than the patents Trisalus Life Sciences, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 33 patents it holds.
Back to Trisalus Life Sciences, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,918,648 | Combination of a PD-1 Antagonist and Cpg-C Type Oligonucleotide for Treating Cancer now held by Merck Sharp & Dohme LLC In force · Medium confidence | In force | Medium confidence | |
| US 10,751,412 | Combination of a PD-1 Antagonist and Cpg-C Type Oligonucleotide for Treating Cancer now held by Merck Sharp & Dohme LLC In force · High confidence | In force | High confidence | |
| US 8,158,768 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |
| US 8,871,732 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |
| US 9,422,564 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |
| US 10,196,643 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |
| US 11,312,965 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |
| US 8,372,413 | Immunomodulatory Polynucleotides and Methods of Using the Same Term ended Term ended Feb 2, 2023 · Medium confidence | Term ended | Term ended Feb 2, 2023 | Medium confidence |
| 15/064,158 | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment Abandoned Abandoned Apr 15, 2019 | Abandoned | Abandoned Apr 15, 2019 | |
| 15/871,871 | Injection Port for Therapeutic Delivery Abandoned Abandoned Jul 28, 2020 | Abandoned | Abandoned Jul 28, 2020 |